Related Experiment Video
Updated: Aug 30, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
[Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a
A J Scheen1, P J Lefèbvre, H Kulbertus
1Services de Diabétologie, Nutrition et Maladies métaboliques et de Médecine interne générale, Département de Médecine, CHU Sart Tilman, Liège.
Insights
A proposed "polypill" combining six drugs could significantly reduce cardiovascular events and strokes. This strategy aims for broad cardiovascular disease prevention in high-risk individuals, pending clinical trial validation.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Context:
- Cardiovascular diseases remain a leading cause of mortality worldwide.
- Current prevention strategies focus on individual risk factor management.
- Meta-analyses suggest significant risk reduction with combined interventions.
Purpose:
- To propose a novel paradigm for cardiovascular disease (CVD) prevention.
- To introduce the concept of a fixed-dose "polypill" for widespread use.
- To evaluate the potential benefits and drawbacks of this new strategy.
Summary:
- A literature review indicates that addressing four key cardiovascular risk factors could reduce ischemic heart disease by 88% and strokes by 80% in at-risk populations.
- The proposed "polypill" includes a statin, three antihypertensive drugs, aspirin, and folic acid, intended for systematic prescription.
- This approach targets individuals with a history of cardiovascular events, vascular disease, diabetes, or those aged 55 and older, irrespective of their baseline risk factor levels.
Impact:
- Potential for a simplified and highly effective approach to cardiovascular disease prevention.
- May lead to a paradigm shift in how cardiovascular risk is managed globally.
- Requires large-scale clinical trials to confirm efficacy and superiority over traditional methods.
Abstract:
In the June 28, 2003 issue of the British Medical Journal, an extensive literature survey based on various large meta-analyses of the efficacy and safety of the reduction of four cardiovascular risk factors (cholesterol, arterial blood pressure, platelet aggregation, homocysteine) leads to the conclusion that a combined pharmacological intervention should reduce ischaemic heart disease events by 88% and strokes by 80% in at risk individuals. Therefore, a new paradigm is proposed for the prevention of cardiovascular diseases. This new strategy would consist in the systematic prescription to people with a history of heart attack or stroke, those with any form of obliterative atherosclerotic vascular disease or diabetes, and everyone aged 55 and older of a fixed combination of 6 pharmacological agents independently of initial risk factor profile.... Such pharmacological formulation, called "polypill", should contain a statin, three blood pressure lowering drugs (each at half standard dose), aspirin (75 mg/day) and folic acid (0.8 mg/day). We discuss the pros and cons of this new paradigm. However, the efficacy of such "polypill" remains to be demonstrated in a large controlled clinical trial as well as its superiority as compared to a classical approach of cardiovascular prevention based upon the individual optimal correction of each risk factor thanks a dose titration of each pharmacological compound.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Cardiovascular Drugs: Classification based on Therapeutic Indications